Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ARK E021

Next Previous
X
Search
Drug Profile

ARK E021

Alternative Names: ARK-E021

Latest Information Update: 16 Mar 2020

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator M Arkin 1999 Ltd
  • Developer Foamix; M Arkin 1999 Ltd
  • Class Antiacnes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acne vulgaris

Most Recent Events

  • 09 Mar 2020 Foamix has been acquired by Menlo Therapeutics
  • 31 Oct 2013 M Arkin 1999 Ltd and Foamix complete a phase I/II trial in Acne vulgaris in Israel (NCT01494285)
  • 30 Jun 2012 Phase-I/II clinical trials in Acne vulgaris in Israel (Topical)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top